Stocks · News reference
Emergent BioSolutions has secured a contract modification from the U.S. Department of Defense valued at up to $22.3 million to supply its BioThrax vaccine.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts from Erste Group Research issued a positive assessment regarding Mayr-Melnhof Karton's agreement to sell 70 percent of its packaging business to KPS Capital Partners.
Emergent BioSolutions announced that members of its senior management team will participate in the upcoming Jefferies Global Healthcare Conference in London.
Erste Group Bank AG has been mandated as a Joint Lead-Manager to organize fixed-income meetings for a potential issuance of Additional Tier 1 subordinated notes by Nova Ljubljanska banka d.d.
Erste Group Bank AG and its subsidiary Erste Bank Polska S.A. have announced a joint investment in the Innovate PL FoF program to support private equity, private debt, and venture capital funds.
Emergent BioSolutions updated its full-year 2026 revenue guidance to $600-645 million amid competitive pressures in its commercial drug business. The company is implementing $40 million in annualized cost-cutting measures and expanding international medical countermeasures sales to 13 countries. While NARCAN faces pricing pressure and market competition, it maintains its leading market position. Management is focusing on operational efficiency, debt reduction, and pipeline execution to support long-term recovery.